Term
| has a 60-70% enzyme activity: AA change from Arg to Cys (need dose reduction in warfarin) |
|
Definition
|
|
Term
| has a 5% enzyme activity: AA change from Ile to Leu (need major dose reduction in warfarin) |
|
Definition
|
|
Term
| predominantly occur in individual of African descent. Require lower warfarin doses |
|
Definition
|
|
Term
| highest in Asian (99%), Caucasian (60%), African Americans (26%) |
|
Definition
|
|
Term
| target enzyme for warfarin which affects the pharmacodynamics |
|
Definition
|
|
Term
|
Definition
|
|
Term
| 5 non-coding SNPs in linkage disequilibrium form two common haplotypes (A and B) |
|
Definition
|
|
Term
| genotypes for loci cleared by the FDA as an in vitro diagnostic device |
|
Definition
|
|
Term
| genotypes for one locus cleared by the FDA as an in vitro diagnostic device |
|
Definition
|
|
Term
| test NOT commercially available |
|
Definition
|
|
Term
| defined as muscle pain or weakness with elevated creatinine kinase levels |
|
Definition
|
|
Term
| talked about synonymous SNP variants with no change to AA but had effects on Efavirenz, Cyclosporine |
|
Definition
|
|
Term
| expressed on the cell membrane and acts as a pump that removes drug within the cell |
|
Definition
| multidrug resistance pumps (MRPs) |
|
|
Term
| important for statin transport into the hepatocyte |
|
Definition
| organic anion transporters (OAT) |
|
|
Term
| encodes for the organic anion transporting polypeptide C (OAT1B1) |
|
Definition
|
|
Term
|
Definition
| organic anion transporting polypeptide C |
|
|
Term
| transports statins (except Fluvastatin!) to hepatocytes |
|
Definition
|
|
Term
| SNP (5521T>C) nucleotide change results in amino acid change |
|
Definition
|
|
Term
|
Definition
| reduces OAT1B1 transport activity --> increased drug plasma concentrations possibly causing toxicity (myopathy) |
|
|
Term
| highest in Caucasian (16%), Asian (10-16%), African Americans (1-2%) |
|
Definition
|
|
Term
| encodes for Kinesin-like Protein 6 |
|
Definition
|
|
Term
| associated with an increased risk of CHD (statins are not able to be transported along microtubules) |
|
Definition
|
|
Term
| highest in African Americans (83%); Asian (39-56%) and Caucasian (36%) |
|
Definition
|
|
Term
| PROVE IT-TIMI 22 study showed that KIF6 719Arg carriers benefit |
|
Definition
| high statin doses (Atorvastatin 80 mg/day compared to pravastatin 40 mg/day) |
|
|
Term
| did NOT benefit from high-dose statin therapy |
|
Definition
|
|
Term
| high-dose statins should be avoided in patients with this allele to reduce potential risk for myopathy; lower dose or consider Fluvastatin (high dose) |
|
Definition
|
|
Term
| testing is commercially available and costs about $500 |
|
Definition
| SLCO1B1*5 and KIF6 719Trp/Arg genotypes |
|
|
